The role of heparan sulfate (HS) in endocrine fibroblast growth factor (FGF) signaling has not been defined. Results: Endocrine FGF mutants devoid of HS binding retain full metabolic activity. Conclusion: HS is dispensable for the metabolic activity of endocrine FGFs. Significance: The study provides new insights into the composition of the cell surface signaling complex of endocrine FGFs.
Background:
The role of heparan sulfate (HS) in endocrine fibroblast growth factor (FGF) signaling has not been defined. Results: Endocrine FGF mutants devoid of HS binding retain full metabolic activity. Conclusion: HS is dispensable for the metabolic activity of endocrine FGFs. Significance: The study provides new insights into the composition of the cell surface signaling complex of endocrine FGFs. In support of our model, we convert a paracrine FGF into an endocrine ligand by diminishing heparan sulfate binding affinity of the paracrine FGF and substituting its Cterminal tail for that of an endocrine FGF containing the Klotho co-receptor binding site in order to home the ligand into the target tissue. Besides serving as a proof of concept, the ligand conversion provides a novel strategy for engineering endocrine FGF-like molecules for the treatment of metabolic disorders, including global epidemics such as type 2 diabetes and obesity.
--------------------
Fibroblast growth factor (FGF) signaling is essential for mammalian development and metabolism (1, 2) . The eighteen mammalian FGFs are grouped into five paracrine-acting subfamilies and one endocrine-acting subfamily comprising FGF19, FGF21 and FGF23 (2, 3) . FGFs mediate their actions by binding and activating FGF receptor tyrosine kinases (FGFRs). There are four FGFR genes in mammals (FGFR1-4) (4), and tissue-specific alternative splicing of FGFR1-3 generates "b" and "c" splice isoforms with distinct ligand-binding specificity (5) (6) (7) (8) (9) (10) . Paracrine FGFs direct multiple processes during embryogenesis, including gastrulation, somitogenesis, organogenesis, and tissue patterning (2, 11, 12) , and also regulate tissue homeostasis in the adult (13, 14) . Endocrine FGFs control major metabolic processes such as bile acid homeostasis (15) , and hepatic glucose and protein metabolism (16, 17) (FGF19), glucose and lipid metabolism (18-21) (FGF21), and phosphate and vitamin D homeostasis (22, 23 ) (FGF23). Thus, these ligands have attracted much attention as potential drugs for the treatment of various inherited or acquired metabolic disorders (1, 24) .
FGFs share a core homology region of about one hundred and twenty amino acids that fold into a β-trefoil (25) (26) (27) (28) consisting of twelve β strands in paracrine FGFs (β1-β12) and eleven β strands in endocrine FGFs (β1-β10 and β12) (3, 29) . The conserved core region is flanked by divergent Nand C-termini, which play a critical role in conferring distinct biological activity on FGFs (3, 8) . All FGFs interact with pericellular heparan sulfate (HS) glycosaminoglycans albeit with different affinities (30) . The HS-binding site of FGFs is comprised of the β1-β2 loop and the region between β10 and β12 strands (3) . HS interacts with both side chain and main chain atoms of the HS-binding site in paracrine FGFs ( Fig. 1A ; (31) ). The HS-binding site of endocrine FGFs deviates from the common conformation adopted by paracrine FGFs such that interaction of HS with backbone atoms of the HS-binding site is precluded (29) . As a result, compared to paracrine FGFs, endocrine FGFs exhibit poor affinity for HS (1, 30) . The poor HS affinity enables these ligands to diffuse freely away from the site of their secretion and enter the blood circulation to reach their distant target organs (29, 30) . By contrast, owing to their high HS affinity (30) , paracrine FGFs are mostly immobilized in the vicinity of the cells secreting these ligands, and hence can only act within the same organ. There is emerging evidence that differences in HS-binding affinity among paracrine FGFs translate into the formation of ligand-specific gradients in the pericellular matrix (32, 33) , which contribute to the distinct functions of these ligands (1, 2) .
Besides controlling ligand diffusion in the extracellular space, HS promotes the formation of the 2:2 paracrine FGF-FGFR signal transduction unit ( Fig. 1D ; (31, 34) (39, 40) .
Klotho co-receptors constitutively associate with FGFRs to enhance the binding affinity of endocrine FGFs for their cognate FGFRs in target tissues (35) (36) (37) (38) . αKlotho is the co-receptor for FGF23 (36, 38) , and βKlotho is the co-receptor for both FGF19 and FGF21 (35, 37) . The C-terminal region of endocrine FGFs mediates binding of these ligands to the FGFR-α/βKlotho co-receptor complex (29, (41) (42) (43) (44) (45) .
Endocrine FGFs still possess residual HSbinding affinity, and moreover, there are differences in this residual binding affinity among the endocrine FGFs ( Fig. 3A ; (29)). These observations raise the possibility that HS may play a role in endocrine FGF signaling (Fig. 1D) . Indeed, there are several reports showing that HS can promote endocrine FGF signaling in the presence as well as in the absence of Klotho coreceptor. It has been shown that HS augments the mitogenic signal elicited by endocrine FGFs in BaF3 cells over-expressing FGFR and Klotho coreceptor by at least two-fold (46) . In addition, even in the absence of Klotho co-receptor, HS enables endocrine FGFs to induce proliferation of BaF3 cells over-expressing FGFR (47, 48) . Compared to paracrine FGFs, however, significantly higher concentrations of both ligand and HS are needed, and the proliferative response of cells to endocrine FGFs still lags behind that of paracrine FGFs by about one order of magnitude (48) .
To decipher the role of HS in endocrine FGF signaling, we generated FGF19 and FGF23 mutant ligands devoid of HS binding and compared their signaling capacity with that of wild-type ligands. Our data show that the mutated ligands retain full metabolic activity demonstrating that HS does not participate in the formation of the endocrine FGF signaling complex. In support of this finding, we convert a paracrine FGF into an endocrine ligand by diminishing HS-binding affinity and replacing the C-terminal tail of the paracrine FGF with that of an endocrine FGF. Importantly, the ligand conversion provides a novel strategy for engineering endocrine FGF-like ligands for therapeutic purposes.
EXPERIMENTAL PROCEDURES
Purification of FGF, FGFR, and Klotho Proteins -The N-terminally hexahistidine-tagged, mature form of human FGF19 (R23 to K216), human FGF21 (H29 to S209; Fig. 5A ), and human FGF23 (Y25 to I251; Fig. 5A ) was refolded in vitro from bacterial inclusion bodies, and purified by published protocols (49, 50) . HS-binding site mutants of FGF19 (K149A) and FGF23 (R140A/R143A) were purified from bacterial inclusion bodies by similar protocols as the wildtype proteins. In order to minimize proteolysis of FGF23 wild-type and mutant proteins, arginine residues 176 and 179 of the proteolytic cleavage site 176 RXXR 179 were replaced with glutamine as it occurs in the phosphate wasting disorder "autosomal dominant hypophosphatemic rickets" (ADHR) (22, 51) . Human FGF1 (M1 to D155), human FGF2 (M1 to S155; Fig. 5A ), and human FGF homologous factor 1B (FHF1B; M1 to T181) were purified by published protocols (50, 52 Fig. 5A ) were purified from the soluble bacterial cell lysate fraction by ionexchange and size-exclusion chromatographies. In order to minimize proteolysis of the chimeras containing the C-terminal sequence from R161 to I251 of FGF23, arginine residues 176 and 179 of the proteolytic cleavage site 176 RXXR 179 located within this sequence were replaced with glutamine as it occurs in ADHR (22, 51) . In addition, in order to prevent disulfide-mediated dimerization of FGF2 and chimeric FGF2 proteins, cysteine residues 78 and 96 were mutated to serine. The Nterminally hexahistidine-tagged C-terminal tail peptide of FGF23 (S180 to I251, termed FGF23 Ctail ) was purified by a published protocol (41) . The ligand-binding domain of human FGFR1c (D142 to R365) was refolded in vitro from bacterial inclusion bodies, and purified by published protocols (49, 50) . The ectodomain of murine αKlotho (A35 to K982) and the ectodomain of murine βKlotho (F53 to L995) were expressed in HEK293 cells as fusion proteins with a C-terminal FLAG tag (36, 53) . The binary complex of FGFR1c ligand-binding domain with αKlotho ectodomain (referred to as αKlotho-FGFR1c complex) was prepared by a published protocol (41) . The binary complex of FGFR1c ligandbinding domain with βKlotho ectodomain (referred to as βKlotho-FGFR1c complex) was prepared in the same fashion as the αKlotho-FGFR1c complex.
Analysis of FGF-heparin and FGF-FGFR-α/βKlotho Interactions by Surface Plasmon
Resonance Spectroscopy -Surface plasmon resonance (SPR) experiments were performed on a Biacore 2000 instrument (Biacore AB), and the interactions were studied at 25 ºC in HBS-EP buffer (10 mM HEPES-NaOH, pH 7.4, 150 mM NaCl, 3 mM EDTA, 0.005% (v/v) polysorbate 20). To study endocrine FGF-heparin interactions, a heparin chip was prepared by immobilizing biotinylated heparin (Sigma-Aldrich) on flow channels of a research-grade streptavidin chip (Biacore AB). The coupling density was ~ 5 fmol mm -2 of flow channel. To measure binding of chimeric FGF2 proteins to heparin, biotinylated heparin was coupled to a streptavidin chip at an approximately 4-fold lower density as judged based on the binding responses obtained for FGF1. To study FGF-FGFR-α/βKlotho interactions, FGF chips were prepared by covalent coupling of FGF proteins through their free amino groups on flow channels of research grade CM5 chips (Biacore AB). Proteins were injected over a chip at a flow rate of 50 µl min -1 , and at the end of each protein injection (180 and 300 s, respectively), HBS-EP buffer (50 µl min -1 ) was flowed over the chip to monitor dissociation for 180 or 240 s. The heparin chip surface was regenerated by injecting 50 µl of 2.0 M NaCl in 10 mM sodium acetate, pH 4.5. For FGF chips, regeneration was achieved by injecting 2.0 M NaCl in 10 mM sodium/potassium phosphate, pH 6.5. To control for nonspecific binding in experiments where an FGF ligand was immobilized on the chip, FHF1B, which shares structural similarity with FGFs but does not exhibit any FGFR binding (52) , was coupled to the control flow channel of the chip (~ 15-30 fmol mm -2 immobilized on the chip, the control flow channel was left blank. The data were processed with BiaEvaluation software (Biacore AB). For each protein injection over the heparin chip, the nonspecific responses from the control flow channel were subtracted from the responses recorded for the heparin flow channel. Similarly, for each protein injection over a FGF chip, the nonspecific responses from the FHF1B control flow channel were subtracted from the responses recorded for the FGF flow channel. Where possible, equilibrium dissociation constants (K D s) were calculated from fitted saturation binding curves. Fitted binding curves were judged to be accurate based on the distribution of the residuals (even and near zero) and χ 2 (<10% of R max ). To examine whether the K149A mutation abrogates residual heparin binding of FGF19, increasing concentrations of wild-type FGF19 were passed over a heparin chip. Thereafter, the FGF19 K149A mutant was injected over the heparin chip at the highest concentration tested for the wild-type ligand. The effect of the R140A/R143A double mutation in the HS-binding site of FGF23 on residual heparin binding of FGF23 was examined in the same fashion as was the effect of the HS-binding site mutation in FGF19.
To verify that the K128D/R129Q/K134V triple mutation in the HS-binding site of the FGF2 core domain diminishes heparin-binding affinity of the FGF2 core, increasing concentrations of FGF2
ΔHBScore -FGF21 C-tail and FGF2 ΔHBScore -FGF23 Ctail were passed over a heparin chip. As a control, binding of FGF2 WTcore -FGF21 C-tail and FGF2 WTcore -FGF23 C-tail to heparin was studied. To examine whether the FGF2
ΔHBScore -FGF23 Ctail chimera can compete with FGF23 for binding to the αKlotho-FGFR1c complex, FGF23 was immobilized on a chip (~ 16 fmol mm -2 of flow channel).
Increasing concentrations of FGF2
ΔHBScore -FGF23 C-tail were mixed with a fixed concentration of αKlotho-FGFR1c complex in HBS-EP buffer, and the mixtures were injected over the FGF23 chip. As controls, the binding competition was carried out with FGF23 or FGF2 as the competitor in solution. As an additional specificity control, competition of the FGF2
ΔHBScore -FGF23 C-tail chimera with FGF21 for binding to the βKlotho-FGFR1c complex was studied. βKlotho-FGFR1c complex was mixed with FGF2
ΔHBScore -FGF23 C-tail or FGF23 at a molar ratio of 1:10, and the mixture was injected over a chip containing immobilized FGF21 (~ 12 fmol mm -2 of flow channel).
To test whether the FGF2 ΔHBScore -FGF21
C-tail chimera can compete with FGF21 for binding to the βKlotho-FGFR1c complex, increasing concentrations of FGF2 ΔHBScore -FGF21 C-tail were mixed with a fixed concentration of βKlotho-FGFR1c complex in HBS-EP buffer, and the mixtures were passed over a chip containing immobilized FGF21 (~ 19 fmol mm -2 of flow channel). As controls, the binding competition was carried out with FGF21 or FGF2 as the competitor in solution.
As an additional specificity control, competition of the FGF2
ΔHBScore -FGF21 C-tail chimera with FGF23 for binding to the αKlotho-FGFR1c complex was studied. αKlotho-FGFR1c complex was mixed with FGF2
ΔHBScore -FGF21 C-tail or FGF21 at a molar ratio of 1:10, and the mixture was injected over a chip containing immobilized FGF23 (~ 12 fmol mm -2 of flow channel ΔHBScore -FGF21 C-tail chimera can activate FGFR in a βKlotho-dependent fashion, HEK293 cells transfected with murine βKlotho were serum starved overnight and then stimulated for 90 min with FGF2
ΔHBScore -FGF21 C-tail or FGF21 (3 to 300 ng ml -1 ). After stimulation, the cells were lysed (53) , and cellular proteins were resolved on SDS-polyacrylamide gels and transferred to nitrocellulose membranes. The protein blots were probed with antibodies to Egr1 and glyceraldehyde 3-phosphate dehydrogenase (GAPDH). The anti-Egr1 antibody was from Cell Signaling Technology and the anti-GAPDH antibody was from Abcam.
Analysis of CYP7A1 and CYP8B1 mRNA Expression in Murine Liver Tissue -To examine the metabolic activity of the FGF19 K149A mutant in vivo, 6-to 8-week old C57BL/6 mice were fasted overnight and then given intraperitoneally a single dose (1 mg kg body weight -1 ) of FGF19 K149A or FGF19 as a control. 6 h after the injection, the mice were sacrificed, and liver tissue was excised and frozen. Total RNA was isolated from liver tissue, and mRNA levels of cholesterol 7α-hydroxylase (CYP7A1) and sterol 12α-hydroxylase (CYP8B1) were measured using quantitative real time RT-PCR as described previously (15, 55 ΔHBScore -FGF21 C-tail chimera (0.3 mg kg body weight -1 ). As a control, mice were co-injected with insulin plus FGF21. At the indicated time points after the injection (Fig. 7G) , blood was drawn from the tail vein. Glucose concentrations in the blood samples were determined using Bayer Contour ® blood glucose test strips (Bayer Corp.). The Harvard University Animal Care and Research committee board had approved the experiments.
Statistical Analysis -Data are expressed as mean + SEM. A Student's t test or analysis of variance (ANOVA) was used as appropriate to make statistical comparisons. A value of P < 0.05 was considered significant.
RESULTS AND DISCUSSION
HS is Dispensable for the Metabolic Activity of FGF19 and FGF23 -In order to engineer endocrine FGFs devoid of HS binding, we compared the FGF19 crystal structure (PDB ID: 2P23; (29)) with that of FGF2 bound to a heparin hexasaccharide (PDB ID: 1FQ9; (31) ). This analysis shows that solvent-exposed residues K149, Q150, Q152, and R157 of FGF19 lie at the corresponding HS-binding site of this ligand, and hence could account for the residual HS binding of FGF19 (Figs. 1, A and B, and 2) . Likewise, comparative analysis of the FGF23 crystal structure (PDB ID: 2P39; (29) ) with that of heparin-bound FGF2 (PDB ID: 1FQ9; (31)) points to R48, N49, R140, and R143 as candidates mediating the residual HS binding of this ligand (Figs. 1, A and C, and 2 ). In agreement with the structural predictions, replacement of K149 alone in FGF19 with alanine and combined substitution of R140 and R143 in FGF23 for alanine were sufficient to abolish residual HS binding of these ligands (Fig. 3, B-E (Fig. 4B ). These data show that similar to FGF19, FGF23 does not need to bind HS in order to activate FGFR in cultured cells.
To substantiate the findings in cells, we compared the metabolic activity of wild-type and mutated ligands in vivo. Mice were injected with the FGF19 K149A mutant or wild-type FGF19 and liver gene expression of CYP7A1 and CYP8B1, which are key enzymes in the major bile acid biosynthetic pathway (60), was analyzed. Like wild-type FGF19, the FGF19 K149A mutant markedly decreased CYP7A1 and CYP8B1 mRNA levels (Fig. 4C) , demonstrating that knockout of residual HS binding does not affect the metabolic activity of FGF19. To examine whether residual HS binding is also dispensable for the metabolic activity of FGF23, mice were injected with the FGF23 R140A/R143A mutant or wildtype FGF23 and serum phosphate concentrations were measured. The FGF23 R140A/R143A mutant reduced serum phosphate as effectively as wildtype FGF23 (Fig. 4D) . Moreover, when injected into Fgf23 knockout mice, the FGF23 R140A/R143A mutant exhibited as much of phosphate-lowering activity as wild-type FGF23 (Fig. 4D) . These data show that, as in the case of FGF19, abolishment of residual HS binding does not impact the metabolic activity of FGF23 leading us to conclude that HS is not a component of the endocrine FGF signal transduction unit (Fig. 1D) .
Conversion of a Paracrine FGF Into an Endocrine Ligand Confirms that HS is Dispensable for the Metabolic Activity of
Endocrine FGFs -If HS is dispensable for the metabolic activity of endocrine FGFs, then it should be feasible to convert a paracrine FGF into an endocrine FGF by eliminating HS-binding affinity of the paracrine FGF and substituting its C-terminal tail for that of an endocrine FGF containing the Klotho co-receptor binding site. Reducing HS-binding affinity will allow the ligand to freely diffuse and enter the blood circulation while attaching the C-terminal tail of an endocrine FGF will home the ligand into its target tissues. We chose to convert FGF2, a prototypical paracrine FGF, into FGF23-like and FGF21-like ligands. FGF2 was selected as paracrine ligand for this protein engineering exercise because it preferentially binds to the "c" isoform of FGFR1, the principal receptor mediating the metabolic activity of FGF23 (61,62) and FGF21 (35) , respectively. In the crystal structure of heparinbound FGF2 (PDB ID: 1FQ9; (31)), K128, R129, and K134 mediate the majority of hydrogen bonds with heparin and hence mutation of these residues should cause a major reduction in HS-binding affinity of FGF2 (Figs. 1A, 2, and 5A) . Accordingly, these three residues were mutated and then the short C-terminal tail of the mutated FGF2 was replaced with the C-terminal tail of FGF23 (R161 to I251) or the C-terminal tail of FGF21 (P168 to S209) (Fig. 5A) . The resulting chimeras were termed FGF2
ΔHBScore -FGF23 C-tail and FGF2
ΔHBScore -FGF21 ΔHBScore -FGF21 C-tail chimeras should lose the ability to activate FGFR1c in an HS-dependent fashion. To test this, HEK293 cells, which endogenously express FGFR1c, were stimulated with FGF2
ΔHBScore -FGF23
C-tail or FGF2 WTcore -FGF23 C-tail . Induction of protein expression of the transcription factor Egr1, a known downstream mediator of FGF signaling, was used as readout for FGFR activation. As shown in Fig. 5G , the FGF2
C-tail chimera, like native FGF23, was ineffective in inducing Egr1 expression at concentrations at which the FGF2
WTcore -FGF23 C-tail chimera elicited a near maximal effect. The same observations were made for the FGF2
ΔHBScore -FGF21 C-tail chimera (Fig. 5F ). These data show that similar to native FGF23 and FGF21, the FGF2
C-tail and FGF2 ΔHBScore -FGF21 C-tail chimeras have lost the ability to activate FGFR in an HS-dependent, paracrine fashion.
To determine whether the FGF2 ΔHBScore -FGF23 C-tail and FGF2 ΔHBScore -FGF21 C-tail chimeras have gained the ability to signal in a Klotho coreceptor-dependent, endocrine fashion, we first analyzed whether these chimeras can form ternary complexes with FGFR1c and Klotho co-receptor. To this end, a SPR-based binding competition assay was employed. FGF23 was immobilized onto a SPR biosensor chip, and mixtures of a fixed concentration of binary αKlotho-FGFR1c complex with increasing concentrations of FGF2
ΔHBScore -FGF23 C-tail chimera were passed over the chip. FGF2
ΔHBScore -FGF23 C-tail competed, in a dose-dependent fashion, with immobilized FGF23 for binding to the αKlotho-FGFR1c complex (Fig.  6A) , demonstrating that the chimera, like native FGF23 (Fig. 6B) , is able to form a ternary complex with FGFR1c and αKlotho. To test whether the FGF2
ΔHBScore -FGF21 C-tail chimera can likewise form a ternary complex with FGFR1c and βKlotho, FGF21 was coupled to a SPR biosensor chip, and mixtures of the binary βKlotho-FGFR1c ΔHBScore -FGF21
C-tail effectively competed with immobilized FGF21 for binding to the βKlotho-FGFR1c complex (Fig.  7A) , demonstrating that the chimera, like native FGF21 (Fig. 7B) , is capable of binding to the binary complex of FGFR1c and βKlotho. Notably, native FGF2 failed to compete with FGF23 for binding to the αKlotho-FGFR1c complex (Fig. 6C) , and with FGF21 for binding to the βKlotho-FGFR1c complex (Fig. 7C) since it lacks the Klotho co-receptor binding domain. To further confirm the binding specificity of the FGF2 ΔHBScore -FGF23 C-tail chimera for the αKlotho-FGFR1c complex, FGF2
ΔHBScore -FGF23 C-tail and βKlotho-FGFR1c complex were mixed at a molar ratio of 10:1, and the mixture was injected over a chip containing immobilized FGF21.
FGF2
ΔHBScore -FGF23 C-tail , like native FGF23, failed to compete with FGF21 for binding to the βKlotho-FGFR1c complex (Fig. 6, D and E) .
Similarly, the FGF2
ΔHBScore -FGF21 C-tail chimera, like native FGF21, failed to compete with FGF23 for binding to the αKlotho-FGFR1c complex (Fig.  7, D and E) . For the FGF2
ΔHBScore -FGF21
C-tail chimera, we investigated whether it is able to activate FGFR1c in a βKlotho-dependent fashion in cells. HEK293 cells were transfected with βKlotho and then stimulated with FGF2 ΔHBScore -FGF21 C-tail or FGF21. Similar to native FGF21, the FGF2
ΔHBScore -FGF21 C-tail chimera induced Egr1 protein expression in HEK293-βKlotho cells (Fig.  7F) , indicating that the chimera is capable of activating FGFR1c in the presence of βKlotho.
To provide definite proof for the ligand conversion, we tested the metabolic activity of the chimeras in vivo. Specifically, the ability of the FGF2
ΔHBScore -FGF23 C-tail chimera to lower serum phosphate and to reduce renal gene expression of CYP27B1, which catalyzes the conversion of vitamin D into its bioactive form, was examined. Mice were injected with FGF2
C-tail or as controls, FGF23 or FGF2 WTcore -FGF23 C-tail , and serum phosphate concentrations and renal CYP27B1 mRNA levels were measured. Similar to native FGF23, the FGF2
C-tail chimera caused a decrease in serum phosphate in wild-type mice (Fig. 6F) . The chimera also induced a marked decrease in CYP27B1 mRNA levels, just like the native FGF23 ligand (Fig. 6G) . These data show that the FGF2 ΔHBScore -FGF23
C-tail chimera acts as an FGF23-like hormone. Importantly, the FGF2 WTcore -FGF23 C-tail chimera failed to decrease serum phosphate or CYP27B1 mRNA levels (Fig. 6, F and G) . This is expected because, owing to its high affinity for HS, this chimera should be trapped in the vicinity of the injection site and hence not be able to enter the blood circulation. Moreover, these data show that adding the Klotho co-receptor binding site is not sufficient to convert a paracrine FGF into an endocrine ligand. To confirm that the metabolic activity of the FGF2
ΔHBScore -FGF23 C-tail chimera is dependent on αKlotho, αKlotho knockout mice were injected with FGF2
ΔHBScore -FGF23 C-tail or FGF23 as a control, and serum concentrations of phosphate were measured. As shown in Fig. 6F , FGF2
ΔHBScore -FGF23 C-tail failed to lower serum phosphate, demonstrating that the chimera, like native FGF23 (Fig. 6F) , requires αKlotho for metabolic activity.
To determine whether the FGF2 ΔHBScore -FGF21 C-tail chimera exhibits FGF21-like metabolic activity, its ability to potentiate the hypoglycemic effect of insulin was examined (59) . Mice were injected with insulin plus FGF2
ΔHBScore -FGF21 C-tail , insulin plus FGF21, or insulin alone, and blood glucose concentrations were monitored for up to one hour after the injection. Similar to FGF21, the FGF2
ΔHBScore -FGF21 C-tail chimera enhanced the hypoglycemic effect of insulin (Fig. 7G) , demonstrating that the chimera acts as an FGF21-like hormone.
Our ability to convert a paracrine FGF into an endocrine ligand by means of reducing HSbinding affinity of the paracrine FGF and adding the Klotho co-receptor binding site substantiates that HS does not participate in the formation of the endocrine FGF signal transduction unit. The dispensability of HS for the metabolic activity of endocrine FGFs has an intriguing implication as to how these FGFs have evolved to become hormones. It appears that these ligands have lost the requirement to bind HS in order to signal, while acquiring the ability to bind Klotho coreceptors, which is necessary to direct these ligands to their target organs.
In the target tissue, Klotho co-receptors constitutively associate with cognate receptors of endocrine FGFs to offset the inherently low receptor-binding affinity of endocrine FGFs (Fig.  8, B-D; (35-38) ). This low binding affinity is due to the fact that key receptor-binding residues in the β-trefoil core of endocrine FGFs are replaced by residues that are suboptimal for receptor binding (29) . To measure the degree to which Klotho coreceptors enhance the receptor-binding affinity of endocrine FGFs, we conducted SPR experiments using FGF23 and FGFR1c and αKlotho coreceptor as an example. The SPR data show that αKlotho enhances the affinity of FGF23 for FGFR1c by over 20-fold (Fig. 8, D and E) . The affinity of FGF23 for FGFR1c in the presence of αKlotho is comparable to that of FGF2 for FGFR1c in the absence of its HS cofactor (Fig. 8,  A and E). It should be noted, however, that HS further increases the binding affinity of FGF2 for FGFR1c by at least an order of magnitude (63, 64) . Hence, the receptor-binding affinity of FGF23 in the presence of αKlotho co-receptor still is lower than that of FGF2 in the presence of HS cofactor. These observations imply that the signaling capacity of the endocrine FGF signal transduction unit should be weaker than that of the paracrine FGF signaling unit. Indeed, cell-based studies show that even in the presence of their Klotho coreceptor, endocrine FGFs are inferior to paracrine FGFs at activating FGFR-induced intracellular signaling pathways (35, 38) .
Our finding that endocrine FGFs do not need to rely on HS for signaling has another important implication in regard to the role of Klotho coreceptors.
Since FGFR dimerization is a prerequisite for FGF signaling in general, we propose that Klotho co-receptors not only enhance the binding affinity of endocrine ligand for receptor but also promote receptor dimerization upon ligand binding. In other words, Klotho coreceptors must fulfill the same dual role that HS plays in signaling by paracrine FGFs (Fig. 1D) . Definite proof for the proposed dual role of Klotho co-receptors awaits the determination of the crystal structure of an endocrine FGF-FGFRKlotho ternary complex, which is beyond the scope of this study. The ligand conversion also provides an exciting framework for the rational design of endocrine FGF-like molecules for the treatment of metabolic disorders. An FGF23-like molecule, for example, could be used for the treatment of inherited or acquired hyperphosphatemia, and an FGF21-like molecule for the treatment of type 2 diabetes, obesity, and related metabolic disorders. (31)). HS engages both paracrine FGF and receptor to enhance binding of FGF to its primary and secondary receptors thus promoting receptor dimerization. A question mark denotes whether or not HS is also a component of the endocrine FGF signaling complex. FIGURE 2. Sequence alignment of the endocrine FGFs. The amino acid sequences of the mature human FGF19, FGF21, and FGF23 ligands are aligned. Also included in the alignment is the human sequence of FGF2, a prototypical paracrine FGF, which was used in this study to convert into endocrine FGF ligands. Residue numbers are in parenthesis to the left of the alignment. Secondary structure elements are labeled, and residues containing these elements for known secondary structures are boxed. Gaps (dashes) were introduced to optimize the sequence alignment. The β-trefoil core domain for known FGF crystal structures is shaded gray. Blue bars on top of the alignment indicate the location of the HS-binding regions. HS-binding residues selected for mutagenesis are shaded blue. K149A mutant and heparin (right panel). Heparin was immobilized on a biosensor chip, and increasing concentrations of FGF19 were passed over the chip. Thereafter, FGF19
K149A was injected over the heparin chip at the highest concentration tested for the wild-type ligand. C, Overlay of SPR sensorgrams illustrating binding of FGF23 to heparin (left panel) and lack of interaction between the FGF23 R140A/R143A mutant and heparin (right panel). Heparin was immobilized on a biosensor chip, and increasing concentrations of FGF23 were passed over the chip. FGF23
R140A/R143A was then injected over the heparin chip at the highest concentration tested for the wild-type ligand. 
